- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Dr. Yu Baofa et turma ex Civitatibus Foederatis Americae ediderunt articulum in Acta Gastroenterologiae Research et Practice
2025-02-11
Doctor Yu Baofa et turma Americana coniunctim ediderunt articulum Aestimatio plurium autoanticorporum ad tumorem antigenis adiunctum sicut potentia diagnostica in cancro pancreatico in Acta Gastroenterologiae Research et Practice.
Propositum huius studii erat aestimare significationem clinicam autoantibodiorum contra GNA11, MSLN, GNAS, CEBPA, MDM2, p16, Sui1, Calnuc, PTEN in cancer pancreatici (PC). Totum 33 serum exempla ab aegris PC et 45 serum exemplaria a normali moderatoribus (NC) inclusa sunt, et 9 genera autoantibodium deprehensa sunt utentes enzyme conexo immunosorbenti primordium (ELISA). Aestimare plures ambitus in singulis vel compositionibus uti. Exceptis GNAS anti et calNUC anti, gradus omnium aliorum autoantibodium insigniter altiores fuerunt quam ea quae in coetus normali in potestate sunt. Comparatus cum globo normali (4.9%), frequentia quattuor autoanticorporum, MSLN, p16, PTEN et Sui1, significanter aucta sunt, in 75,8%, 66.7%, 30.3%, et 27,3%, respective. Facultas harum autoantibodium ad distinguendi area sub curva ROC (AUC) vagatur ab 0,666 ad 0,884, cum anti-p16 (A.C. 0,884) et MSLN anti (AUC 0,857) exhibens efficacissimam diagnostica effectum. Compositum anti-MSLN et anti-p16 sensum diagnosi emendare potest.
Praeterea, tum MSLN et Sui1 autoantibodies in PC aegris post chemotherapyem decreverunt. Quattuor autoantibodia contra MSLN, p16, Sui1 et PTEN ostenderunt notas potentiales diagnosticae pro cancer pancreatici, quarum anti MSLN et anti p16 optimae fuerunt. Coniunctio horum duorum autoantibodium maxime demonstrat potentialem oeconomicam et practicam. Significatio autoanticorporum minutorum contra MSLN et Sui1 in PC aegris post chemotherapyam ulteriore explorationi indiget.
Investigatio de tumore autoanticorporum affinium magni ponderis referentiam praebet pro primo protegendo, diagnosi et curatione tumorum. Academicus Yu Baofa applicavit autoantibodi tumorem in tumore curationis plus quam XX annos.
